Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.2300-0.1000 (-4.29%)
At close: 04:00PM EDT
2.1800 -0.05 (-2.24%)
After hours: 06:27PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-190,099
-234,632
-183,118
-250,219
-204,472
Depreciation & amortisation
20,234
20,250
18,020
13,624
4,294
Stock-based compensation
56,984
47,084
81,924
62,201
33,261
Change in working capital
-41,694
3,421
-82,015
4,015
-336
Accounts payable
513
1,464
667
91
-278
Other working capital
-170,569
-166,380
-193,831
-191,753
-212,355
Other non-cash items
-12,409
-4,653
-6,683
4,624
12,047
Net cash provided by operating activities
-163,326
-163,694
-169,555
-126,249
-160,874
Cash flows from investing activities
Investments in property, plant and equipment
-7,243
-2,686
-24,276
-65,504
-51,481
Purchases of investments
-279,764
-476,880
-406,316
-673,465
-908,357
Sales/maturities of investments
618,393
663,614
419,052
617,396
686,322
Net cash used for investing activities
331,386
184,048
-11,540
-121,573
-273,516
Cash flows from financing activities
Common stock issued
-
0
0
391,802
0
Common stock repurchased
-
-
0
0
-16,050
Other financing activities
-428
-457
-461
-
-
Net cash used provided by (used for) financing activities
1,847
1,743
10,635
401,244
476,790
Net change in cash
169,907
22,097
-170,460
153,422
42,400
Cash at beginning of period
116,590
123,834
294,294
140,872
98,472
Cash at end of period
286,497
145,931
123,834
294,294
140,872
Free cash flow
Operating cash flow
-163,326
-163,694
-169,555
-126,249
-160,874
Capital expenditure
-7,243
-2,686
-24,276
-65,504
-51,481
Free cash flow
-170,569
-166,380
-193,831
-191,753
-212,355